GlassScriptPhysician profile
Tapan Pandya
NPI 1104181734
$3,434.36
in general payments reported to CMS, 2019-2025
26 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $251 · 2021: $112 · 2022: $41.78 · 2023: $388 · 2024: $631 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,016.40 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $685.81 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.72 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $243.20 | 2019-2025 | Dupixent |
| Electromed, INC. | $143.90 | 2023-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $117.50 | 2020-2025 | |
| Philips North America LLC | $99.29 | 2019-2024 | (Ak6) Vest Therapy |
| Ani Pharmaceuticals, INC. | $97.03 | 2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $89.25 | 2024-2025 | Zemaira |
| Janssen Pharmaceuticals, INC | $73.66 | 2020-2024 | Xarelto |
| Baxter Healthcare | $64.86 | 2021-2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $59.80 | 2020-2024 | Cuvitru, Hyqvia |
| Advanced Respiratory, INC | $56.86 | 2019-2020 | |
| Abbvie INC. | $50.78 | 2021 | |
| Shire North American Group INC | $41.61 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $39.66 | 2019 | |
| Allergan, INC. | $39.37 | 2019 | |
| Verona Pharma, INC. | $31.13 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $27.49 | 2019 | |
| Pfizer INC. | $26.46 | 2024 | |
| Inspire Medical Systems, INC. | $25.80 | 2024 | Inspire |
| Insmed, INC. | $22.53 | 2024 | Arikayce |
| Lilly USA, LLC | $21.75 | 2025 | Zepbound, Mounjaro |
| Hikma Pharmaceuticals USA | $19.86 | 2025 | Ryaltris |
| E.R. Squibb & Sons, L.L.C. | $19.13 | 2024 | Camzyos |
| Merck Sharp & Dohme LLC | $18.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tapan Pandya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.